USA – Pathalys Pharma, a Raleigh, NC-based private, late-stage biopharma company, raised $150M in Secured Product financing and equity funding.
Abingworth led both financings and was joined by Carlyle and OrbiMed, along with Pathalys’ founding investors Catalys Pacific and DaVita Venture Group. The company intends to use the funds to support the two phase 3 clinical trials, registration efforts and pre-commercialization activities for upacicalcet.Led by CEO Neal Fowler, Pathalys Pharma is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end-stage kidney disease (ESKD). Pathalys’ initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, the company continues to identify other high priority needs and potential solutions for patients with ESKD. Launch Therapeutics (Launch Tx), a clinical development company, today announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Tx is backed by funds managed by global investment firm Carlyle (NASDAQ: CG) and its life sciences franchise Abingworth.20/01/2023
